<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="146076">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01198925</url>
  </required_header>
  <id_info>
    <org_study_id>2010/414</org_study_id>
    <nct_id>NCT01198925</nct_id>
  </id_info>
  <brief_title>Assessment of the Optimal Dosing of Piperacillin-tazobactam in Intensive Care Unit Patients: Extended Versus Continuous Infusion</brief_title>
  <official_title>Assessment of the Optimal Dosing of Piperacillin-tazobactam in Intensive Care Unit Patients: Extended Versus Continuous Infusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Piperacillin-tazobactam is an acylureido-penicillin-beta-lactamase inhibitor combination and
      is frequently used in the empirical treatment of hospital-acquired infections because of its
      antipseudomonal activity. Similar to other beta-lactam antibiotics, piperacillin-tazobactam
      exhibits time-dependent killing and the T &gt; MIC appears to be the best outcome predictor.
      Because a majority of infections are treated empirically, it is necessary to achieve a T &gt;
      MIC equal to 50% of the dosing interval (50% T &gt; MIC) against the most likely pathogens,
      including those with only moderate susceptibility The aim of this study is to compare the
      same dose of piperacillin/tazobactam administered by an extended infusion versus a
      continuous infusion. A pharmacokinetic study will be performed in patients treated by
      extended (loading dose 4 G/30 min followed by 4 X 4 G /3h) and continuous infusion (loading
      dose 4 G/30 min followed by 16G /24h).

      A population pharmacokinetic analysis with Monte Carlo simulations will be used to determine
      95% probability of target attainment (PTA95) versus MIC
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pharmacokinetics of piperacillin continuous infusion compared to piperacillin extended infusion</measure>
    <time_frame>6 hours</time_frame>
    <description>Determination of serum concentrations of piperacillin.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>95% probability of target attainment (PTA95) versus MIC of different organisms.</measure>
    <time_frame>96 hours</time_frame>
    <description>Determination of the probability of target attainment versus MIC of different organisms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Infectious Disease</condition>
  <arm_group>
    <arm_group_label>extended infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>continuous infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>piperacillin continuous infusion</intervention_name>
    <description>piperacillin continuous infusion</description>
    <arm_group_label>continuous infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>piperacillin extended infusion</intervention_name>
    <description>piperacillin extended infusion</description>
    <arm_group_label>extended infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (&gt; 18 years) admitted on the intensive care unit (surgical and medical
             surgery).

          -  Starting a treatment with piperacillin/tazobactam

          -  Signed informed consent

          -  Hematocrit &gt;= 21%

          -  Available arterial line

        Exclusion Criteria:

          -  age &lt;18 or &gt;75 years

          -  patient's weight &lt;50 or &gt;100 kg

          -  renal insufficiency (estimated clearance &lt; 50 ML /MIN)

          -  haemodialysis

          -  WBC &lt; 1000 103 Âµl

          -  estimated survival &lt;5 days

          -  meningitis or other proven infections of the CNS

          -  IgE-mediated allergy to penicillins

          -  pregnancy

          -  patients having participated in another study &lt;30 days before inclusion in the
             present study

          -  retrospectively, marked deterioration of the renal function during the study period

          -  retrospectively, treatment &lt; 96 h
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johan Decruyenaere, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Ghent, Belgium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johan Decruyenaere, MD, PhD</last_name>
    <email>johan.decruyenaere@ugent.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Ghent</name>
      <address>
        <city>Ghent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Johan Decruyenaere, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://www.uzgent.be</url>
    <description>website University Hospital Ghent, Belgium</description>
  </link>
  <verification_date>December 2014</verification_date>
  <lastchanged_date>December 4, 2014</lastchanged_date>
  <firstreceived_date>September 8, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Infectious disease</keyword>
  <keyword>piperacillin</keyword>
  <keyword>continuous infusion</keyword>
  <keyword>extended infusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Piperacillin, tazobactam drug combination</mesh_term>
    <mesh_term>Penicillanic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
